lenalidomide has been researched along with IgA Vasculitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aouba, A; Audemard-Verger, A; Battistella, M; Bigot, A; Brihaye, B; Cook, AR; Deriaz, S; Diot, E; El Karoui, K; Ferreira-Maldent, N; Hankard, A; Henique, H; Ingen-Housz-Oro, S; Jobard, S; Lioger, B; Magnant, J; Maillot, F; Paule, R | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
2 other study(ies) available for lenalidomide and IgA Vasculitis
| Article | Year |
|---|---|
IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series.
Topics: Bortezomib; Cyclophosphamide; Dexamethasone; Humans; IgA Vasculitis; Immunoglobulin A; Lenalidomide; Melphalan; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Retrospective Studies; Rituximab | 2022 |
Multiple myeloma presenting as cutaneous leukocytoclastic vasculitis and eosinophilia disclosing a T helper type 1/T helper type 2 imbalance: a case report.
Topics: Aged, 80 and over; Bortezomib; Eosinophilia; Female; Humans; IgA Vasculitis; Immunologic Factors; Lenalidomide; Multiple Myeloma; Paraneoplastic Syndromes; Th1 Cells; Th2 Cells; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous | 2018 |